Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 Ng./Ml.: A comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests

Journal of Urology

Volumn 166, Issue 4, 2001, Pages 1339-1342

  Makinen T ^a,b   Tammela, T L J ^a,b   Hakama, M ^a,b   Stenman, U H ^a,b   Rannikko, S ^a,b   Aro, J ^a,b   Juusela, H ^a,b   Maattanen L ^a,b   Auvinen, A ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER SCREENING; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 0034831361     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65764-3     Document Type: Article

References (20)

1. European randomized study of prostate cancer screening: First-year results of the Finnish trial
2. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. prostate specific antigen
3. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng./ml. and benign prostate examination. Enhancement of specificity with free PSA measurements
4. Serum prostate specific antigen as pre-screening test for prostate cancer
5. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4.0 ng./ml. or less
6. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng./ml. and digital rectal examination is not suspicious for prostate cancer: An alternative model
7. Prostate cancer detection at low prostate specific antigen
8. Histologic grading of prostate cancer: A perspective
9. Evaluation of the digital rectal examination as a screening test for prostate cancer
10. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam)
11. Latent carcinoma of prostate at autopsy in seven areas
12. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease
13. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng./ml. total PSA
14. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population
15. The appropriate lower limit for the percent free prostate-specific antigen reflex range
16. Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
17. Results of conservative management of clinically localized prostate cancer
18. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
19. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma